HUP0500734A2 - 2-Alkoxifenil-csoporttal szubsztituált imidazotriazinon-származékok alkalmazása - Google Patents
2-Alkoxifenil-csoporttal szubsztituált imidazotriazinon-származékok alkalmazásaInfo
- Publication number
- HUP0500734A2 HUP0500734A2 HU0500734A HUP0500734A HUP0500734A2 HU P0500734 A2 HUP0500734 A2 HU P0500734A2 HU 0500734 A HU0500734 A HU 0500734A HU P0500734 A HUP0500734 A HU P0500734A HU P0500734 A2 HUP0500734 A2 HU P0500734A2
- Authority
- HU
- Hungary
- Prior art keywords
- disorders
- imidazotriazinones
- substituted
- alkoxyphenyl
- preeclampsia
- Prior art date
Links
- IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical class O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 title abstract 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000007984 Female Infertility Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010021928 Infertility female Diseases 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000005107 Premature Birth Diseases 0.000 abstract 1
- 206010036590 Premature baby Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 208000029162 bladder disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000030135 gastric motility Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
A találmány ismert 2-helyzetben fenilcsoporttal szubsztituált, 9-helyzetben rövid, el nem ágazó alkilcsoportokat tartalmazó és cGMP PDEinhibitor tulajdonságokkal rendelkező imidazotriazinonok alkalmazásáravonatkozik szívelégtelenség, pszoriázis, női terméketlenség, rák,cukorbetegség, szemészeti rendellenességek, így glaukóma,gyomormotilitási rendellenességek, cisztás fibrózis, koraszülés, tüdőmagas vérnyomás, hólyag rendellenességek, prosztata jóindulatúmegnagyobbodása, nitrát által indukált tolerancia, preeklampszia,alopécia, Parkinson-kór, fájdalom, tinnitusz vagy veseszindrómakezelésére szolgáló gyógyszerek előállítására.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10135815A DE10135815A1 (de) | 2001-07-23 | 2001-07-23 | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| PCT/EP2002/007959 WO2003011262A2 (de) | 2001-07-23 | 2002-07-17 | Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0500734A2 true HUP0500734A2 (hu) | 2005-11-28 |
| HUP0500734A3 HUP0500734A3 (en) | 2005-12-28 |
Family
ID=7692784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0500734A HUP0500734A3 (en) | 2001-07-23 | 2002-07-17 | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6930108B2 (hu) |
| EP (2) | EP1474150B1 (hu) |
| JP (1) | JP2005504751A (hu) |
| KR (1) | KR20040032865A (hu) |
| CN (1) | CN1649593A (hu) |
| AT (1) | ATE442144T1 (hu) |
| AU (1) | AU2002319296B2 (hu) |
| BG (1) | BG108533A (hu) |
| BR (1) | BR0211359A (hu) |
| CA (1) | CA2454414A1 (hu) |
| CO (1) | CO5560536A2 (hu) |
| CZ (1) | CZ2004128A3 (hu) |
| DE (2) | DE10135815A1 (hu) |
| EC (1) | ECSP044956A (hu) |
| EE (1) | EE200400056A (hu) |
| ES (1) | ES2330418T3 (hu) |
| HR (1) | HRP20040065A2 (hu) |
| HU (1) | HUP0500734A3 (hu) |
| IL (1) | IL159840A0 (hu) |
| MA (1) | MA26128A1 (hu) |
| MX (1) | MXPA04000675A (hu) |
| NO (1) | NO20040294L (hu) |
| NZ (1) | NZ530703A (hu) |
| PL (1) | PL373392A1 (hu) |
| RU (1) | RU2321406C9 (hu) |
| SK (1) | SK442004A3 (hu) |
| UA (1) | UA76997C2 (hu) |
| WO (1) | WO2003011262A2 (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| DE102004023069A1 (de) | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
| ME01609B (me) | 2005-04-19 | 2014-09-20 | Takeda Gmbh | Roflumilast za liječenje pulmonarne hipertenzije |
| EP2521721B1 (en) * | 2009-12-30 | 2014-10-01 | Shanghai Fochon Pharmaceutical Co. Ltd | 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors |
| AT512084A1 (de) * | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
| EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| EP3554506B1 (en) * | 2016-12-16 | 2021-04-28 | Cystic Fibrosis Foundation | Bycyclic heteroaryl derivatives as cftr potentiators |
| CN113461694A (zh) * | 2021-08-05 | 2021-10-01 | 广东西捷药业有限公司 | 一种伐地那非类似物及其合成方法和应用 |
| CN113583003A (zh) * | 2021-08-05 | 2021-11-02 | 广东西捷药业有限公司 | 一种伐地那非类似物及其合成方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791025A (fr) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
| GB1457873A (en) | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
| DK109578A (da) * | 1977-03-25 | 1978-09-26 | Allen & Hanburys Ltd | Fremgangsmaade til fremstilling af heterocycliske forbindelser |
| US4308384A (en) | 1978-09-18 | 1981-12-29 | Glaxo Group Limited | Production of triazinones |
| US4479210A (en) * | 1982-11-19 | 1984-10-23 | U.S. Philips Corporation | Record-disc player |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
| DE69622031T2 (de) * | 1995-04-10 | 2002-12-12 | Fujisawa Pharmaceutical Co | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN |
| ATE303365T1 (de) * | 1995-12-28 | 2005-09-15 | Fujisawa Pharmaceutical Co | Benzimidazolderivate |
| CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| DE19881732D2 (de) | 1997-11-12 | 2000-08-24 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren |
| DE19812462A1 (de) * | 1998-03-23 | 1999-09-30 | Bayer Ag | 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid |
| JP4307719B2 (ja) * | 1997-12-12 | 2009-08-05 | セル パスウェイズ インコーポレイテッド | 新形成治療用のｎ−ベンジル−３−インデニルアセトアミド誘導体 |
| US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
| DE19827640A1 (de) | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
| IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
| US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
| FR2792634B1 (fr) * | 1999-04-20 | 2001-06-01 | Synthelabo | Derives de 2-alcoxy-cyclobutene-3,4-dione leur preparation et leur application en therapeutique |
| IL130968A (en) * | 1999-07-15 | 2002-12-01 | Shmuel Simon | Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss |
| AU775102B2 (en) * | 1999-09-13 | 2004-07-15 | David M. Swope | Composition and method for decreasing neurologic symptomatology |
| DE19943815A1 (de) * | 1999-09-14 | 2001-03-15 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| CA2323008C (en) | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Pharmaceutically active compounds |
| DE50013571D1 (de) * | 1999-10-12 | 2006-11-16 | Lilly Icos Llc | Arzneimittel zur behandlung von neuropathien |
| IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2406947A1 (en) * | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| US20020006926A1 (en) * | 2000-04-19 | 2002-01-17 | Roylance H. H. | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| CN1446084A (zh) * | 2000-08-11 | 2003-10-01 | 辉瑞大药厂 | 胰岛素抗性综合症的治疗 |
| AU2001286832A1 (en) * | 2000-08-30 | 2002-03-13 | Lilly Icos Llc | Method for treatment of migraine using PDE5 inhibitors |
| GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
| WO2002060422A2 (en) * | 2001-02-02 | 2002-08-08 | Pfizer Limited | Treatment of diabetes mellitus using vardenafil |
| DE10107639A1 (de) * | 2001-02-15 | 2002-08-22 | Bayer Ag | 2-Alkoxyphenyl-substituierte Imidazotriazinone |
| JP4540295B2 (ja) * | 2001-05-09 | 2010-09-08 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | ２−フェニル置換イミダゾトリアジノンの新しい用途 |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
| WO2003074082A1 (en) * | 2002-03-06 | 2003-09-12 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics in cancer treatment |
-
2001
- 2001-07-23 DE DE10135815A patent/DE10135815A1/de not_active Withdrawn
-
2002
- 2002-07-17 US US10/483,462 patent/US6930108B2/en not_active Expired - Fee Related
- 2002-07-17 IL IL15984002A patent/IL159840A0/xx unknown
- 2002-07-17 SK SK44-2004A patent/SK442004A3/sk not_active Application Discontinuation
- 2002-07-17 AT AT02748858T patent/ATE442144T1/de not_active IP Right Cessation
- 2002-07-17 BR BR0211359-7A patent/BR0211359A/pt not_active IP Right Cessation
- 2002-07-17 EP EP02748858A patent/EP1474150B1/de not_active Expired - Lifetime
- 2002-07-17 CZ CZ2004128A patent/CZ2004128A3/cs unknown
- 2002-07-17 PL PL02373392A patent/PL373392A1/xx not_active Application Discontinuation
- 2002-07-17 ES ES02748858T patent/ES2330418T3/es not_active Expired - Lifetime
- 2002-07-17 EE EEP200400056A patent/EE200400056A/xx unknown
- 2002-07-17 DE DE50213840T patent/DE50213840D1/de not_active Expired - Fee Related
- 2002-07-17 RU RU2004105265/15A patent/RU2321406C9/ru not_active IP Right Cessation
- 2002-07-17 NZ NZ530703A patent/NZ530703A/en unknown
- 2002-07-17 UA UA2004021279A patent/UA76997C2/uk unknown
- 2002-07-17 JP JP2003516493A patent/JP2005504751A/ja active Pending
- 2002-07-17 KR KR10-2004-7001050A patent/KR20040032865A/ko not_active Application Discontinuation
- 2002-07-17 HU HU0500734A patent/HUP0500734A3/hu unknown
- 2002-07-17 CN CNA028144759A patent/CN1649593A/zh active Pending
- 2002-07-17 EP EP06017257A patent/EP1733728A3/de not_active Withdrawn
- 2002-07-17 AU AU2002319296A patent/AU2002319296B2/en not_active Ceased
- 2002-07-17 CA CA002454414A patent/CA2454414A1/en not_active Abandoned
- 2002-07-17 WO PCT/EP2002/007959 patent/WO2003011262A2/de active Application Filing
- 2002-07-17 MX MXPA04000675A patent/MXPA04000675A/es active IP Right Grant
-
2004
- 2004-01-14 BG BG108533A patent/BG108533A/bg unknown
- 2004-01-19 EC EC2004004956A patent/ECSP044956A/es unknown
- 2004-01-22 HR HRP20040065 patent/HRP20040065A2/xx not_active Application Discontinuation
- 2004-01-22 NO NO20040294A patent/NO20040294L/no not_active Application Discontinuation
- 2004-01-22 MA MA27497A patent/MA26128A1/fr unknown
- 2004-02-23 CO CO04015666A patent/CO5560536A2/es not_active Application Discontinuation
-
2005
- 2005-06-17 US US11/156,082 patent/US7276504B2/en not_active Expired - Fee Related
-
2007
- 2007-10-01 US US11/906,382 patent/US20080085897A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0500734A2 (hu) | 2-Alkoxifenil-csoporttal szubsztituált imidazotriazinon-származékok alkalmazása | |
| WO2002085248A3 (en) | Prostanoids augment ocular drug penetration | |
| BR0207325A (pt) | Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1 | |
| ATE265056T1 (de) | Progressive additionslinsen mit variabelen brechkraftprofilen | |
| MXPA02009327A (es) | Lente de contacto que tiene un perfil de espesor horizontal uniforme. | |
| EP1381280A4 (en) | VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS | |
| WO2005099702A3 (en) | R(-)-11-hydroxyaporphine derivatives and uses thereof | |
| PE20030473A1 (es) | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular | |
| SE0002934D0 (sv) | New aporphine esters and in their use in therapy | |
| TW200507822A (en) | Hypertension descending device | |
| BR0017163A (pt) | Derivados 5-hidróxi-indazol para tratamento do glaucoma | |
| MXPA03002914A (es) | Compuestos quimicos. | |
| CN205485116U (zh) | 眼镜 | |
| WO2003046139A3 (en) | CRBs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHOD OF USE | |
| BR0109192A (pt) | Tratamento de hipertensão ocular e glaucoma. | |
| WO2001083688A3 (fr) | Nouveau polypeptide, sous-unite humaine 13 phosphatidylinositol-4-phosphate-5-kinase ii beta, et polynucleotide codant pour ce polypeptide | |
| WO2002047697A3 (en) | Fractions of snake blood, their preparation and use as therapeutic agents | |
| McNeill | Light of my life: 60 years of British tubular fluorescent lighting | |
| WO2001075023A3 (fr) | Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase humaine 9, et polynucleotide codant pour ce polypeptide | |
| WO2001081537A3 (fr) | Nouveau polypeptide, sous-unite 49 humaine du facteur c(a1) 37kd de replication de l'adn, et polynucleotide codant pour ce polypeptide | |
| BR0208146A (pt) | Uso de propentofilina para controlar pressão intra-ocular | |
| WO2001075054A3 (fr) | Nouveau polypeptide, facteur humain de regulation 30 de la transcription de la microglobuline, et polynucleotide codant pour ce polypeptide | |
| WO2002078698A3 (fr) | Polarisation de cellules dendritiques (traitement des infections, du cancer et des maladies auto-immunes) par l'histamine | |
| WO2001075014A3 (fr) | Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase 35 humaine, et polynucleotide codant pour ce polypeptide | |
| WO2001075062A3 (fr) | Nouveau polypeptide, hydrogenase humaine 10, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE Free format text: FORMER OWNER(S): BAYER HEALTHCARE AG, DE |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |